Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckRobert L. Ferris, Maura L. Gillison, Tamara Rordorf et al.|New England Journal of Medicine|2016Cited by 5.1k
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trialKevin J. Harrington, J. Guigay, Robert L. Ferris et al.|The Lancet Oncology|2017Cited by 431
General population normative data for the EQ-5D-3L in the five largest European economiesMathieu F. Janssen, James W. Shaw|The European Journal of Health Economics|2021Cited by 58
Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141.Robert L. Ferris, Maura L. Gillison, George R. Blumenschein et al.|Journal of Clinical Oncology|2016Cited by 53
Treatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomesRobert I. Haddad, Robert L. Ferris, George R. Blumenschein et al.|Annals of Oncology|2017Cited by 36